PPF aims for control of Zentiva board; Sinclair snaps up Novo Pharma;

> PPF has sued the Czech generics maker Zentiva for a special shareholders meeting, in hopes of moving its own slate of directors onto the board and perhaps derailing Sanofi-Aventis' planned acquisition of the company. Report

> Sinclair Pharma bought the 49.95 percent of Laboratorios Novo Pharma that it didn't already own, giving it wholly owned operations in France, Italy, U.K. and Spain. Report

> Eugene Melnyk, the former chairman of Biovail, Canada's largest publicly traded drugmaker, agreed to pay $1 million to settle a claim in a U.S. Securities and Exchange Commission lawsuit. Report

> Haupt Pharma, a contract manufacturer and developer, bought a Pfizer production site in Latina, Italy, that focused on the production of antibiotics, especially beta-lactams like penicillin and cephalosporin. Report

> Galderma got the FDA nod for Vectical Ointment, a vitamin D3 product for treating plaque psoriasis in adults. Release

> Shares of Eli Lilly sparked up ward Tuesday afternoon after the cardiovascular committee at the FDA unanimously recommended approval of its would-be blockbuster prasugrel. Report

> With its big rivals all busy making headlines with their plans for market-shaking acquisitions, Merck says it is leaving the sidelines and taking the M&A field. Report

> BioMarin Pharmaceutical out of Novato, CA says that its mid-stage trial of 6R-BH4 for peripheral arterial disease missed both its primary and secondary goals. Report

> After losing $575 million in its last quarter, the board at MDS has bowed to the intense pressure of its critics and begun to explore the sale of some of its assets. Report

And Finally... Cleveland Clinic researchers say they may have found a way to help Tysabri patients who develop the rare brain infection progressive multifocal leukoencephalopathy. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.